With this investment, the Group strengthens its offer in point of care medical biology and positions itself in the digitalization of diagnostics
Usense’s connected in vitro medical device can perform urinalysis with results obtained in seconds. (Credit: Niek Verlaan from Pixabay.)
Eurobio Scientific, a leading French group in the field of specialty in vitro medical diagnostics, announces today that it made a minority investment in Usense, a French start-up based in Paris-Saclay and specializing in assistance to medical diagnostics based on urinary analysis.
Using a proprietary blend of miniaturized technologies and artificial intelligence, Usense’s connected in vitro medical device can perform urinalysis with results obtained in seconds. The medical device is lightweight and portable, which allows it to be used as close as possible to patients, where the information is necessary for medical diagnosis. The company plans to start marketing the device in 2022.
A key investment for the dynamics of the Eurobio Scientific Group
This investment fits directly with Eurobio Scientific’s strategy. It allows the gradual increase of its share of proprietary products in its catalog, as well as the conquest of new markets by strengthening its presence in point of care biology and digitalization of diagnostics.
“We were impressed with the patented technologies implemented in Usense’s solution, with an accuracy confirmed by real-life testing. This investment allows our Group to immediately set foot in the future of diagnostics.” adds Jean-Michel Carle, President and CEO of Eurobio Scientific.
“We are very proud of Eurobio Scientific’s participation in this financing. For Usense, this is the first step in a long-term partnership. Synergies between the two companies will accelerate the deployment of the Usense solution and facilitate access to early diagnosis for patients.” concludes Guillaume Lemetais, President of Usense.
Source: Company Press Release